Researchers in Spain and Switzerland have identified a molecule that may transform how medicine approaches Alzheimer's disease, not by targeting the amyloid plaques that accumulate in the brain, but by restoring the brain's own immune cells to a state in which they can fight those plaques themselves.
The molecule, called OLE — short for N-oleoyl-Leucine — was derived from the PM20D1 gene, which has previously been identified as an Alzheimer's disease risk gene. The study, published in Cell Death & Disease and announced June 19, 2026, was led by Jose Vicente Sanchez Mut of the Institute for Neurosciences (IN), a joint center of the Spanish National Research Council (CSIC). The research team included investigators from multiple institutions in Spain and Switzerland.
